Articles

Given the high prevalence of Kawasaki disease during the pandemic, Japanese investigators determined that droplet or contact transmission of pathogens is likely not a major route causing the development of the disease.

COVID-19 Pandemic Provides Glimpse Into Potential Cause of Kawasaki Disease in Children

An investigation examines which infants might require screening before peanut introduction.

Should Some Infants be Screened Before Peanut Introduction?

Diagnosis, risk assessment and treatment of congenital melanocytic nevi (CMN), as well as melanoma, require specific strategies for pediatric patients.

Optimize Risk, Management of Pigmented Lesions in Pediatric Patients

John Jesitus is a medical writer based in Westminster, CO.

With up to 30% of pediatric health care visits involving skin complaints and fewer than 400 board-certified pediatric dermatologists in the United States, teledermatology offers a valuable tool for increasing access and cutting wait times.

Pediatric Teledermatology Adds Access, Cuts Wait Times 

Spending time around animals as an infant has been suggested as a way to reduce the incidence of atopic dermatitis. An investigation offers some insight.

Can Early Exposure to Farm Animals Reduce AD Risk?  ­

While Mohs micrographic surgery is well established as a safe and effective therapeutic modality in adult patients, it is not as commonly used in pediatric populations. There are unique challenges to performing Mohs surgery on pediatric patients, especially with patient cooperation. Multidisciplinary planning may be needed.

Mohs micrographic presents challenges in kids 

Infants with eczema may require different approaches to preventing food allergies, including early introduction of peanuts to increase oral exposure to allergens before skin exposure.

Infant eczema impacts food allergy plan 

In a recent phase 3 trial, dupilumab (Dupixent, Sanofi and Regeneron) demonstrated positive results in itch reduction, skin clearance and quality-of-life. Indicating the biologic as a viable treatment option for severe atopic dermatitis in younger children.  

Dupilumab provides option for severe AD in younger children 

The U.S. FDA has approved to expand the indication for golimumab (SIMPONI ARIA, Janssen Pharmaceutical Companies of Johnson & Johnson) to include it was a treatment for active psoriatic arthritis (PsA) in pediatric patients 2 years and older.

FDA expands golimumab indication 

Videos

In the final part of our interview with Candrice Heath, M.D., she discusses some of the treatment challenges associated with treating pediatric patients with skin of color and how to overcome these obstacles.

Pediatric Dermatology